Scorpius Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeff A. Wolf
- Full Time Employees
- 90
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1305 East Houston Street San Antonio TX United States of America 78205
- IPO Date
- Jul 24, 2013
- CIK
- 0001476963
- Website
- scorpiusbiologics.com
- Similar Companies
- Business
- Scorpius Holdings, Inc. (SCPX) operates as an integrated contract development and manufacturing organization (CDMO) through its subsidiary Scorpius BioManufacturing, providing comprehensive biologics services to pharmaceutical and biotechnology companies; core offerings encompass clinical and commercial drug substance manufacturing, release and stability testing, upstream and downstream process development and optimization, analytical method development, cell line development testing and characterization, cGMP manufacturing for mammalian and microbial protein modalities including plasmid DNA production, bioanalytical services, protein refolding from inclusion bodies, formulation and fill-finish in nine cleanrooms at its San Antonio, Texas facility. Founded in 2008 and headquartered in San Antonio, Texas, with corporate offices in Morrisville, North Carolina, the company serves the biopharmaceutical industry with a focus on advancing biologic programs from preclinical to clinical stages and beyond, emphasizing U.S.-based supply chain security and flexible high-quality biomanufacturing. Recent developments include a February 2024 name change from NightHawk Biosciences, Inc., the launch of Scorpius Ventures offering a hybrid fee-for-service and equity model to support U.S. biotech onshoring aligned with the BIOSECURE Act, strategic collaborations with KaloCyte for ErythroMer manufacturing enhancements, Celltheon Corporation for cell line development, a U.S. biotech for GMP opportunities, and Beyond Imagination for AI-powered humanoid robots in biomanufacturing, alongside engagement of Alliance Global Partners to explore strategic alternatives, cost-saving measures targeting over $2 million annually, selection for the Medical CBRN Defense Consortium, and pursuit of halal-certified biomanufacturing expansion opportunities in Southeast Asia particularly with Malaysia.
Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™
Scorpius Holdings Cancels Planned Reverse Stock Split
Scorpius Holdings Announces Reverse Stock Split
Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement
Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually
Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow
Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
Scorpius Holdings, Inc. Announces Closing of Public Offering
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering
Why Is Scorpius (SCPX) Stock Down 79% Today?
Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024